Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $43.00

Posted by on Aug 7th, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $43.00.

A number of research analysts recently weighed in on STOK shares. Canaccord Genuity Group dropped their price target on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings cut Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wedbush boosted their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday. Guggenheim reaffirmed a “buy” rating and set a $60.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Tuesday.

Read Our Latest Stock Analysis on Stoke Therapeutics

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares in the company, valued at approximately $541,675.70. The trade was a 7.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 7,176 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the transaction, the insider owned 20,422 shares in the company, valued at approximately $593,054.88. The trade was a 26.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 10,428 shares of company stock valued at $306,919 in the last 90 days. 9.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its position in shares of Stoke Therapeutics by 333.8% during the fourth quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after buying an additional 1,116,452 shares during the last quarter. State Street Corp grew its stake in shares of Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares in the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Stoke Therapeutics in the second quarter valued at about $7,489,000. Troluce Capital Advisors LLC bought a new stake in shares of Stoke Therapeutics during the 1st quarter worth $21,255,000. Finally, BVF Inc. IL grew its holdings in Stoke Therapeutics by 36.7% during the fourth quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after purchasing an additional 608,578 shares during the period.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $31.93 on Tuesday. The firm has a market cap of $2.06 billion, a PE ratio of -9.56 and a beta of 1.20. Stoke Therapeutics has a 52-week low of $12.86 and a 52-week high of $40.22. The business’s 50 day moving average price is $30.41 and its two-hundred day moving average price is $32.05.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. Research analysts predict that Stoke Therapeutics will post -3.41 EPS for the current fiscal year.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

  • Positive Sentiment: Wedbush raised its price target to $40 and maintained an “outperform” rating, while Chardan Capital reiterated “buy” with a $35 target. Canaccord retained a “buy” rating despite lowering its target to $58. The broader analyst consensus remains “Moderate Buy,” with an average target of $43. Wedbush price-target update
  • Positive Sentiment: Investors continue to focus on Stoke’s pipeline. Management plans to submit a rolling NDA for zorevunersen in the first quarter of 2027 for SCN1A-related Dravet syndrome, while continuing development of STK-002. Approximately $420 million in cash could support these programs and potential launch preparations. Pipeline and NDA outlook
  • Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, giving management an opportunity to provide updates on its clinical and regulatory plans. Conference presentation announcement
  • Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026–2028: FY2026 to a loss of $3.35 per share from $3.09, FY2027 to a loss of $2.55 from $2.05, and FY2028 to a loss of $1.78 from $0.67. It also lowered quarterly estimates to losses of $0.81 per share. These revisions point to slower progress toward profitability. HC Wainwright earnings estimates
  • Negative Sentiment: Stoke’s second-quarter loss of $0.93 per share exceeded the expected loss of $0.80, although revenue of approximately $9.33 million surpassed estimates. The company remains deeply unprofitable, increasing investor sensitivity to cash use and development execution. Second-quarter earnings summary
  • Negative Sentiment: Director Barry Ticho sold 7,176 shares for approximately $208,000, reducing his stake by 26%. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which limits its significance but may still weigh modestly on sentiment. SEC insider-sale filing

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Featured Stories

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.